Metastatic and Recurrent Cervical Cancer Treatment

Role of Surgery in advanced and recurrent cervical cancer, Basel RefkyПодробнее

Role of Surgery in advanced and recurrent cervical cancer, Basel Refky

The innovaTV 301 TrialПодробнее

The innovaTV 301 Trial

All Hands on Deck in Cervical Cancer Care: Screening, Treatment, and EquityПодробнее

All Hands on Deck in Cervical Cancer Care: Screening, Treatment, and Equity

Combining cemiplimab and ISA101b for the treatment of recurrent/metastatic HPV16 cervical cancerПодробнее

Combining cemiplimab and ISA101b for the treatment of recurrent/metastatic HPV16 cervical cancer

Management and Care of Patients with Invasive Cervical Cancer: Resource-Stratified Guideline Rapi...Подробнее

Management and Care of Patients with Invasive Cervical Cancer: Resource-Stratified Guideline Rapi...

Cervical Cancer Survivorship: A Patient's PerspectiveПодробнее

Cervical Cancer Survivorship: A Patient's Perspective

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Подробнее

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

The innovaTV 301 TrialПодробнее

The innovaTV 301 Trial

All Hands on Deck in Cervical Cancer CareПодробнее

All Hands on Deck in Cervical Cancer Care

(Subtitle) Why Cancer Metastasis and Recurrence Occur after Therapy? #chemotherapy #radiotherapyПодробнее

(Subtitle) Why Cancer Metastasis and Recurrence Occur after Therapy? #chemotherapy #radiotherapy

Updates for the management of advanced and recurrent Cervical Cancer - Prof. Mohsen MokhtarПодробнее

Updates for the management of advanced and recurrent Cervical Cancer - Prof. Mohsen Mokhtar

Highlights on Tisotumab Vedotin 2L or 3L Recurrent or Metastatic Cervical Cancer: innovaTV 301Подробнее

Highlights on Tisotumab Vedotin 2L or 3L Recurrent or Metastatic Cervical Cancer: innovaTV 301

What's New in Cervical Cancer: 2023 UpdatesПодробнее

What's New in Cervical Cancer: 2023 Updates

AdvanTIG-202: tislelizumab ± ociperlimab in recurrent/metastatic cervical cancerПодробнее

AdvanTIG-202: tislelizumab ± ociperlimab in recurrent/metastatic cervical cancer

Recurrent/Metastatic Human Papillomavirus-Associated Oropharynx Cancer: What Happens When This Go...Подробнее

Recurrent/Metastatic Human Papillomavirus-Associated Oropharynx Cancer: What Happens When This Go...

Jill's Envita Review - Recurrent Metastatic Cervical Cancer TreatmentПодробнее

Jill's Envita Review - Recurrent Metastatic Cervical Cancer Treatment

Guideline-based treatment of recurrent/metastatic cervical cancerПодробнее

Guideline-based treatment of recurrent/metastatic cervical cancer

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/...Подробнее

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/...

AdvanTIG-202: tislelizumab +/- ociperlimab in recurrent/metastatic cervical cancerПодробнее

AdvanTIG-202: tislelizumab +/- ociperlimab in recurrent/metastatic cervical cancer

Tisotumab Vedotin for Metastatic Cervical Cancer: Results From ESMO 2023 With Brian Slomovitz, MDПодробнее

Tisotumab Vedotin for Metastatic Cervical Cancer: Results From ESMO 2023 With Brian Slomovitz, MD